Esperion (ESPR)
NASDAQ:ESPR
ESPR Stock Chart & Stats
$2.17
-$0.02(-0.92%)
At close: 4:00 PM EST
$2.17
-$0.02(-0.92%)
Day’s Range― - ―
52-Week Range$0.69 - $4.18
Previous CloseN/A
Volume1.55M
Average Volume (3M)5.73M
Market Cap
$557.28M
Enterprise Value$831.31M
Total Cash (Recent Filing)$167.85M
Total Debt (Recent Filing)$548.00M
Price to Earnings (P/E)―
Beta2.19
Next Earnings
May 12, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.22
Shares Outstanding256,810,500
10 Day Avg. Volume6,083,521
30 Day Avg. Volume5,734,082
Financial Highlights & Ratios
PEG Ratio0.56
Price to Book (P/B)-2.55
Price to Sales (P/S)1.91
P/FCF Ratio-59.60
Enterprise Value/Market Cap1.49
Enterprise Value/Revenue2.06
Enterprise Value/Gross Profit3.20
Enterprise Value/Ebitda13.24
Forecast
1Y Price Target
$7.30Price Target Upside236.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)0.07
Revenue Forecast (FY)$410.58M
Bulls Say, Bears Say
Bulls Say
Acquisition And Pipeline DiversificationAnalyst views the acquisition of Corstasis and integration of Enbumyst as strategic moves that broaden the product portfolio and position the company to evolve into a multiproduct cardiometabolic firm.
Commercial Strategy And Real‑world EvidenceAnalyst highlights a well‑established U.S. commercial strategy, growing international footprint, and real‑world evidence that support expanded prescriptions and market access for Nexletol and Nexlizet.
Guideline EndorsementAnalyst notes updated dyslipidemia guidelines awarded multiple strong recommendations for bempedoic acid, increasing its standing as a non‑statin option for high‑risk and statin‑intolerant patients.
Bears Say
Competitive Threat From New Oral TherapyAnalyst warns that a competing oral therapy from a major drugmaker demonstrated greater LDL reduction and superior tolerability, posing a direct competitive threat to bempedoic acid's market share.
Enbumyst Market UncertaintyAnalyst notes uncertainty about Enbumyst's potential in the congestive heart failure market given existing and emerging competition from MannKind, which may temper expectations for the product's commercial impact.
Payer Access And Cost BarriersAnalyst points out that branded status and patient out‑of‑pocket costs, along with payer and large pharma relationships, could restrict reimbursement and limit broader adoption despite guideline support.
Esperion News
ESPR FAQ
What was Esperion’s price range in the past 12 months?
Esperion lowest stock price was $0.69 and its highest was $4.17 in the past 12 months.
What is Esperion’s market cap?
Esperion’s market cap is $557.28M.
When is Esperion’s upcoming earnings report date?
Esperion’s upcoming earnings report date is May 12, 2026 which is in 30 days.
How were Esperion’s earnings last quarter?
Esperion released its earnings results on Mar 10, 2026. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.243 by -$0.023.
Is Esperion overvalued?
According to Wall Street analysts Esperion’s price is currently Undervalued.
Does Esperion pay dividends?
Esperion does not currently pay dividends.
What is Esperion’s EPS estimate?
Esperion’s EPS estimate is -0.02.
How many shares outstanding does Esperion have?
Esperion has 256,810,500 shares outstanding.
What happened to Esperion’s price movement after its last earnings report?
Esperion reported an EPS of $0.22 in its last earnings report, missing expectations of $0.243. Following the earnings report the stock price went down -11.184%.
Which hedge fund is a major shareholder of Esperion?
Currently, no hedge funds are holding shares in ESPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Esperion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.30 (236.25% Upside)
$7.30 (236.25% Upside)
Blogger Sentiment
Neutral
ESPR Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 968.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $106.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
126.04%
12-Months-Change
Fundamentals
Return on Equity
5.62%
Trailing 12-Months
Asset Growth
155.90%
Trailing 12-Months
Company Description
Esperion
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
ESPR Company Deck
ESPR Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong commercial and financial highlights: record revenue growth (Q4 +144%), meaningful U.S. product momentum (U.S. sales +38%; Rx equivalents +34%; prescribers +~25%), expanding international adoption (Daiichi +51% royalties; >700,000 patients treated), a stronger balance sheet ($167.9M cash and $55M debt paid), and a strategic acquisition (Corstasis/Enbumyst) that broadens market opportunity. Lowlights were largely transitional or one-time in nature: a large nonrecurring collaboration payment in 2025 that reduces revenue comparability in 2026, rising SG&A/legal costs tied to litigation, modestly higher R&D and operating expense guidance to fund integration and launches, and near-term uncertainty from guideline timing and competitive entrants. Overall, the positives — robust growth, global rollout, pipeline advancement, and a transformative acquisition — outweigh the manageable near-term challenges and one-time items.View all ESPR earnings summariesESPR Stock 12 Month Forecast
Average Price Target
$7.30
▲(236.25% Upside)
Technical Analysis
Ownership Overview
1.86% Insiders
12.24% Mutual Funds
19.22% Other Institutional Investors
55.25% Public Companies and
Individual Investors